#Torrent Pharma Derma Products torrent

Its purpose has always been to launch specialty niche products to address unmet medical needs arising from major life threatening diseases and reach out to maximum number of patients to offer cost effective treatment with latest quality drugs.

#Torrent Pharma Derma Products torrent

Regarding the expected business from these biosimilars, Executive Director - Marketing of Torrent Pharma Mr.Ruchir Modi said that since inception, its focus was never with business intent alone, rather it is a by product. Torrent is already marketing biosimilar Rituximab вЂToritzвЂ™ in Oncology segment, while a super specialty division for Nephrology launched in 2014 is marketing biosimilar Darbepoetin alpha - вЂDarbatitorвЂ™. Moreover, the company has also launched Hep B Antiviral Tenofovir вЂ“ вЂTenocruzвЂ™. Torrent has launched new generation Hep C Antiviral Sofosbuvir вЂ“ вЂSofocruzвЂ™, a combination of Sofosbuvir + Ledipasvir - вЂSofocruz LPвЂ™ and Daclatasvir вЂ“ вЂDaclacruzвЂ™.

This super speciality team, besides promoting biosimilar Adalimumab вЂ“ вЂAdfrar IBвЂ™ to Gastroenterologists, will also cater to the advanced therapy needs in Hepatology. Around 100 highly trained professionals are employed in these Greenfield divisions. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India, for which three separate super specialty task force have been introduced. вЂAdfrarвЂ™ will be available as Pre Filled Syringe of 40mg. TorrentвЂ™s brand вЂAdfrarвЂ™ will be the second biosimilar Adalimumab in the world.ДЄutoimmune disorders are growing ailments and Monoclonal Antibodies (MAbвЂ™s) are becoming mainstay of treatment, therefore launch of вЂAdfrarвЂ™ is a significant step towards fortifying its presence in MAb market.Д«iosimilar Rituximab - вЂToritz RAвЂ™ is already launched in Rheumatology segment and now with launch of biosimilar Adalimumab - вЂAdfrarвЂ™, Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality.

Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD). Ahmedabad based Torrent Pharma enters New Year 2016 by announcing the launch of biosimilar Adalimumab in India under the brand name вЂAdfrarвЂ™.ДЄdalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis.